Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm)

Affiliations

Scott A Rivkees. Int J Pediatr Endocrinol. 2009.

. 2009:2009:303509.

doi: 10.1155/2009/303509. Epub 2009 Mar 4.

¹ Yale Child Health Research Center, Yale University School of Medicine, New Haven, CT 06520, USA.

No abstract available

Cited by

Characteristics and trends in adverse drug reactions in Ghana-evidence of spontaneous reports, 2005-2021.
Nyame L, Xue H, Yu J, Fiagbey EDK, Thomford KP, Du W. Nyame L, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):657-672. doi: 10.1007/s00210-024-03302-5. Epub 2024 Jul 23. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39043880
Impact of an educational intervention on pharmacovigilance knowledge and attitudes among health professionals in a Nepal cancer hospital.
Shrestha S, Sharma S, Bhasima R, Kunwor P, Adhikari B, Sapkota B. Shrestha S, et al. BMC Med Educ. 2020 Jun 3;20(1):179. doi: 10.1186/s12909-020-02084-7. BMC Med Educ. 2020. PMID: 32493307 Free PMC article.
Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana.
Yawson AA, Abekah-Nkrumah G, Okai GA, Ofori CG. Yawson AA, et al. Ther Adv Drug Saf. 2022 Aug 6;13:20420986221116468. doi: 10.1177/20420986221116468. eCollection 2022. Ther Adv Drug Saf. 2022. PMID: 35966898 Free PMC article.
Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates.
Güner MD, Ekmekci PE. Güner MD, et al. J Drug Assess. 2019 Jan 5;8(1):13-20. doi: 10.1080/21556660.2019.1566137. eCollection 2019. J Drug Assess. 2019. PMID: 30729064 Free PMC article.

1. Tercica, Inc. INCRELEXTM (mecasermin [rDNA origin] injection), Tercica, Brisbane, Calif, USA, August 2005.
1. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nature Clinical Practice Oncology. 2007;4(10):591–602. - PubMed
1. Rosenbloom AL. The role of recombinant insulin-like growth factor I in the treatment of the short child. Current Opinion in Pediatrics. 2007;19(4):458–464. - PubMed
1. Strom BL, Melmon KL, Miettinen OS. Post-marketing studies of drug efficacy: why? The American Journal of Medicine. 1985;78(3):475–480. - PubMed
1. Torjusen E, Calderon J, Rivkees SA. Anaphylactic reaction to recombinant insulin-like growth factor-I. Journal of Pediatric Endocrinology & Metabolism. 2008;21(4):381–384. - PubMed